Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

View ORCID ProfileBayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Cristina Camargo, Gwang-Jin Kim, David O. Carpenter
doi: https://doi.org/10.1101/2021.10.24.21265450
Bayarmagnai Weinstein
1Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
2Department of Environmental Health Sciences, School of Public Health, University at Albany, Rensselaer, NY 12144, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bayarmagnai Weinstein
  • For correspondence: bmunkhjargal{at}albany.edu
Bogdan Muresan
3Health Sciences Unit, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Solano
1Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Vaz de Macedo
1Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
4Hematology Clinic, Hospital da Polícia Militar, Belo Horizonte, MG, CEP 30110-013, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YoonJung Lee
5Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Chen Su
6Inari Medical, Biostatistics and Programming Dept, Irvine, CA 92618, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yeseul Ahn
5Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela Henriquez
1Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
7Iberoamerican University, Santo Domingo 10203, Dominican Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Camargo
8School of Medicine, Univesida de São Paulo, Brazil CEP 01246903
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwang-Jin Kim
9Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David O. Carpenter
2Department of Environmental Health Sciences, School of Public Health, University at Albany, Rensselaer, NY 12144, USA
10Institute for Health and the Environment, University at Albany, Rensselaer, NY 12144, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/- ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable efficacy and safety, whereas the co-infusion of CD19 & CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.

NOVELTY AND IMPACT Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://journal.ppcr.org/index.php/ppcrjournal/article/view/142

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • To update the Title of the manuscript

Data Availability

Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.

https://journal.ppcr.org/index.php/ppcrjournal/article/view/142

  • ABBREVIATIONS

    ASCT
    autologous stem cell transplantation
    B-ALL
    B-cell acute lymphoblastic leukemia
    BCMA
    B-cell maturation antigen
    CAR
    chimeric antigen receptor
    CD
    cluster of differentiation
    ChiCTR
    Chinese clinical trial registry
    CI
    confidence interval
    CR
    complete response
    CRES
    car T cell-related encephalopathy syndrome
    CRR
    complete response rate
    CRS
    cytokine release syndrome
    CRS
    cytokine release syndrome
    DLBCL
    diffuse large B-cell lymphoma
    DOR
    duration of response
    EFS
    event-free survival
    ESS
    effective sample size
    HGBCL
    high-grade B-cell lymphoma
    HR
    hazard ratio
    Hu
    human
    IFN-γ
    interferon-γ
    IL-2
    interleukins-2
    IPD
    individual patient data
    KM
    Kaplan-Meier
    LBCL
    large B-cell lymphoma
    MAIC
    matching adjusted indirect comparisons
    NCT
    national clinical trial
    NHL
    non-Hodgkin lymphoma
    NT
    neurotoxicity
    OR
    odds ratio
    ORR
    objective response rate
    OS
    overall survival
    PFS
    progression free survival
    PH
    proportional hazards
    PPCR
    principles and practice of clinical research
    PRISMA
    preferred reporting items for systematic reviews and meta-analyses
    R/R LBCL
    relapsed/refractory large B-cell lymphoma
    RR
    relative risk
    RS
    Richter’s transformation
    scFv
    single-chain variable fragment
    SD
    stable disease
    TNF-α
    tumor necrosis factor-α
    trDLBCL
    transformed DLBCL
    ZUMA-1
    name of Yescarta clinical trial
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted October 28, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LB…
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
    Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Cristina Camargo, Gwang-Jin Kim, David O. Carpenter
    medRxiv 2021.10.24.21265450; doi: https://doi.org/10.1101/2021.10.24.21265450
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
    Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Cristina Camargo, Gwang-Jin Kim, David O. Carpenter
    medRxiv 2021.10.24.21265450; doi: https://doi.org/10.1101/2021.10.24.21265450

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)